STAT+: A biotech hedge fund births a new immunology company
Why a biotech hedge fund decided to build from the ground up a new company to develop a better, long-acting antibody treatment for atopic dermatitis.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.